Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program ...

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising ...

A new study found that the immunotherapy treatment worked against some types of cancers, allowing patients to avoid surgery ...

Janux Therapeutics, Inc.’s JANX share price has dipped by 10.52%, which has investors questioning if this is right time to buy.

Glioblastoma may be driven by 3D DNA folding patterns, not just mutations, offering new paths for treatment. A new ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

States with higher tax income were found to have increased cancer screening rates and decreased cancer mortality rates, ...

According to a statement issued on Monday by the Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro, the ...

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA c ...

Ontada to present 14 data presentations at ISPOR 2025 including a podium presentation on distress thermometer screening in US oncology setting ...

Patients with certain types of early stage cancer, particularly those affecting the gastrointestinal system, may be able to ...

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, May 5, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST) to report its financial results ...